Diurnal variations in twenty-four-hour energy expenditure during growth hormone treatment of adults with pituitary deficiency

J Clin Endocrinol Metab. 1997 Apr;82(4):1255-60. doi: 10.1210/jcem.82.4.3855.

Abstract

The effects of growth hormone (GH) treatment on 24-h energy expenditure (EE) were studied in a open trial over a period of 4 weeks. Five subjects, four men and one woman, with a history of complete GH deficiency were included. All the subjects were examined on 2 consecutive days on baseline and, thereafter, at six occasions during a period of 1 month (days 1, 2, 5, 8, 15, and 30). The dose of GH was 0.25 U/kg.week, administered sc once a day in the evening. EE was determined in a chamber for indirect calorimetry. Body composition was determined with dual-energy x-ray absorptiometry and computed tomography using a four-scan technique. Blood samples were examined using well-established RIAs. During the first 2 weeks, 24-h EE increased by 6 +/- 3% (range 1-8%) from 40.9 +/- 4.8 to 42.9 +/- 4.8 kcal/24 h.kg (P < 0.05), sleeping metabolic rate by 14 +/- 3% (range 10-18%) from 28.4 +/- 1.9 to 32.9 +/- 2.2 kcal/24h.kg (P < 0.001), and basal metabolic rate by 11 +/- 7% (range 0-18%) from 29.6 +/- 2.4 to 33.3 +/- 2.6 kcal/24h.kg (P < 0.05). No change was found in daytime EE. The increase in EE covaried with changes in insulin-like growth factor 1, the free T3/free T4 ratio, insulin-like growth factor-binding protein-3, and the aminoterminal procollagen III peptide but not with changes in body composition. It is suggested that the stimulating effect of GH on EE occurs gradually during a 2-week period and is only detectable during night and morning hours, when significant levels of GH occur.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers
  • Body Composition
  • Circadian Rhythm*
  • Energy Metabolism*
  • Female
  • Human Growth Hormone / deficiency*
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / blood
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Middle Aged
  • Peptide Fragments / blood
  • Pituitary Diseases / drug therapy*
  • Pituitary Diseases / pathology
  • Procollagen / blood
  • Thyroid Hormones / blood

Substances

  • Biomarkers
  • Insulin-Like Growth Factor Binding Protein 3
  • Peptide Fragments
  • Procollagen
  • Thyroid Hormones
  • procollagen Type III-N-terminal peptide
  • Human Growth Hormone
  • Insulin-Like Growth Factor I